
1. j trop med hyg. 2011 dec;85(6):984-8. doi: 10.4269/ajtmh.2011.11-0260.

inhibitory activity ferroquine, versus chloroquine, western kenya
plasmodium falciparum field isolates determined sybr green vitro assay.

eyase fl(1), akala hm, johnson jd, walsh ds.

author information: 
(1)department emerging infectious diseases program, u.s. army medical research
unit-kenya, kenya medical research institute-walter reed project, kisumu, kenya. 
feyase@wrp-ksm.org

ferroquine (fq), chloroquine (cq) analog, developed treat persons
with plasmodium falciparum malaria. 146 p. falciparum field isolates from
western kenya, measured 50% inhibitory concentrations (ic(50); nm) cq and
fq sybr green vitro assay. reference clones included w2 (cq resistant) 
and d6 (cq sensitive). mutation analysis done p. falciparum cq-resistance
transporter gene (pfcrt k76t). median ic(50) values fq lower cq for
field isolates w2 clone (both p < 0.05). pfcrt mutation (76t), 
was detected > 80% isolates, conferred higher cq ic(50) values (p < 0.05)
and modestly lower fq ic(50) values (p < 0.05), versus pfcrt wild type (k76). fq 
is potent cq cq-resistant p. falciparum field isolates 
w2 clone, less affected pfcrt 76t. findings support notion
that fq could useful treating persons p. falciparum malaria.

doi: 10.4269/ajtmh.2011.11-0260 
pmcid: pmc3225175
pmid: 22144431  [indexed medline]

